FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+30.23%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$1.87B
AUM Growth
+$1.87B
(+24%)
Cap. Flow
+$70.6M
Cap. Flow
% of AUM
3.78%
Top 10 Holdings %
Top 10 Hldgs %
59.4%
Holding
56
New
5
Increased
14
Reduced
4
Closed
7
Top Buys
| 1 |
89bio
ETNB
|
$22.3M |
| 2 |
Edgewise Therapeutics
EWTX
|
$19.9M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$16.2M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$16.1M |
| 5 |
Dyne Therapeutics
DYN
|
$15.8M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$42.4M |
| 2 |
Enliven Therapeutics
ELVN
|
$14.3M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$8.71M |
| 4 |
Replimune Group
REPL
|
$6.62M |
| 5 |
Prothena Corp
PRTA
|
$6.17M |
Sector Composition
| 1 | Healthcare | 99.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$3.71B
| $192M | 10.25% | 6,495,392 +25,000 | +0.4% | +$738K |
|
2
HilleVax
HLVX
$105M
| $157M | 8.39% | 9,781,472 | – | – |
|
3
NewAmsterdam Pharma
NAMS
$2.71B
| $136M | 7.25% | 12,131,705 | – | – |
|
4
Krystal Biotech
KRYS
$4.27B
| $123M | 6.56% | 988,460 | – | – |
|
5
BridgeBio Pharma
BBIO
$9.89B
| $110M | 5.88% | 2,725,949 | – | – |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $109M | 5.83% | 2,371,304 | – | – |
|
7
Phathom Pharmaceuticals
PHAT
$864M
| $92.3M | 4.93% | 10,109,279 | – | – |
|
8
Vaxcyte
PCVX
$4B
| $73.1M | 3.91% | 1,164,405 | – | – |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $59.9M | 3.2% | 3,014,349 | – | – |
|
|
ALPN
10
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $59.7M | 3.19% | 3,131,008 +145,251 | +5% | +$2.77M |
|
|
11
Apellis Pharmaceuticals
APLS
$3.48B
| $53M | 2.83% | 885,165 +271,122 | +44% | +$16.2M |
|
12
Rocket Pharmaceuticals
RCKT
$354M
| $45.6M | 2.44% | 1,523,013 +120,000 | +9% | +$3.6M |
|
13
Disc Medicine
IRON
$2.07B
| $45.3M | 2.42% | 785,000 +130,000 | +20% | +$7.51M |
|
14
KalVista Pharmaceuticals
KALV
$678M
| $44.4M | 2.37% | 3,622,294 +383,435 | +12% | +$4.7M |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $36.2M | 1.94% | 1,787,527 | – | – |
|
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $29.2M | 1.56% | 2,667,203 +1,818,181 | +214% | +$19.9M |
|
17
Revolution Medicines
RVMD
$7.1B
| $28.6M | 1.53% | 997,455 | – | – |
|
18
AN2 Therapeutics
ANTX
$30.1M
| $28.5M | 1.52% | 1,388,889 | – | – |
|
19
Arcutis Biotherapeutics
ARQT
$1.86B
| $28.3M | 1.51% | 8,764,232 +80,000 | +0.9% | +$258K |
|
|
JBIO
20
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $27.3M | 1.46% | 1,204,867 | – | – |
|
|
AUTL
21
Autolus Therapeutics
AUTL
$399M
| $24.1M | 1.29% | 3,746,857 | – | – |
|
22
MacroGenics
MGNX
$112M
| $23.1M | 1.24% | 2,401,704 +598,500 | +33% | +$5.76M |
|
23
Acadia Pharmaceuticals
ACAD
$4.38B
| $22.9M | 1.22% | 730,917 +100,020 | +16% | +$3.13M |
|
|
24
89bio
ETNB
$1.34B
| $22.3M | 1.19% | +2,000,000 | New | +$22.3M |
|
25
Merus
MRUS
$4.98B
| $20.5M | 1.1% | 746,479 | – | – |
|